Cytori Therapeutics (NSDQ:CYTX) touted the publication of preclinical safety and efficacy data for its cell therapy treatment for combined radiation and thermal injury.
The San Diego-based company said the current healthcare system is ill-prepared to care for large numbers of patients that require simultaneous treatment and that patients with severe burns commonly suffer with prolonged pain and aggressive scarring. The company touts its autologous cell therapies as a cost-effective way to improve the quality and rate of wound healing, while reducing scarring.
Get the full story at our sister site, Drug Delivery Business News.
The post Cytori touts regenerative cell therapy data appeared first on MassDevice.
from MassDevice http://ift.tt/2dCRkzn
Cap comentari:
Publica un comentari a l'entrada